News

POWL's fiscal Q3 earnings and revenues miss estimates, even as record orders and a $2.4 billion backlog strengthen its outlook.

IDEX (IEX) just released second quarter and first half 2026 results, along with an update on its long running share repurchase program, giving investors fresh numbers to evaluate the stock. See our latest analysis for IDEX. Recent earnings and buyback news come as IDEX trades at US$230.45, with the share price up 28.7% year to date and a 1 year total shareholder return of 46.98%. This points to momentum building over the past year despite a modest pullback in the last trading day. If you are...

IDEX (NYSE:IEX) reported second-quarter 2026 results that exceeded its expectations, supported by growth in its Health & Science Technologies segment, stronger orders and operational execution. The company raised its full-year outlook for organic sales growth, adjusted EBITDA margin and adjusted

Moby summary of IDEX Corporation's Q2 2026 earnings call

IDEX Corp (IEX) reports robust Q2 performance with significant order growth and raises full-year financial outlook.

Idex (IEX) delivered earnings and revenue surprises of +10.48% and +2.01%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

IEX reports Q2 results on July 29, with revenue growth expected as Health & Science demand and acquisitions support sales despite cost pressures.

IDEX Corporation enters Q2 earnings with strong momentum, as Wall Street watches for another solid performance.

IDEX (NYSE:IEX) reported first-quarter 2026 results that management said came in above expectations, supported by growth in its targeted “advantage markets” and continued application of the company’s 80/20 operating philosophy. Quarterly performance and orders President and CEO Eric Ashleman said I

Moby summary of IDEX Corporation's Q1 2026 earnings call

IDEX delivered a strong first quarter and continue to see our growth strategies gain traction as we expand and integrate capabilities in targeted advantaged markets powered by 8020. In the first quarter, IDEX delivered organic sales growth of 5% and adjusted EBITDA margin of 26%, which reflects a margin expansion of 50 basis points year-over-year. Strength was most pronounced in our Health & Science Technologies, or HST segment, where secular drivers continue to fuel growth across high-value applications in data center, semiconductor and space and defense markets.

Idex (IEX) delivered earnings and revenue surprises of +12.68% and +6.20%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?